Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma [Yahoo! Finance]
Lisata Therapeutics, Inc. (LSTA)
Company Research
Source: Yahoo! Finance
treatment of osteosarcoma, a rare type of bone cancer that affects children, adolescents and young adults. Shares of the company were up 4.1% on Apr 9, following the announcement of the news. The FDA grants ODD to support the development of medicines for rare disorders that affect fewer than 200,000 patients in the United States. The ODD will grant Lisata seven-year market exclusivity for LSTA1 for a predefined time period, along with the exemption of FDA application fees and tax credits for qualified clinical studies, all subject to potential approval. LSTA1 is an investigational drug candidate that allows co-administered or tethered anti-cancer drugs to better penetrate solid tumors by activating a novel uptake pathway. The candidate has exhibited the potential to improve the tumor environment, thereby making tumors more responsive to immunotherapy. If successfully developed and upon potential approval, LSTA1 can serve an area of high unmet medical need and help patients by pr
Show less
Read more
Impact Snapshot
Event Time:
LSTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LSTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LSTA alerts
High impacting Lisata Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LSTA
News
- Lisata Therapeutics, Inc. (NASDAQ: LSTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.MarketBeat
- Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors [Yahoo! Finance]Yahoo! Finance
- Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma [Yahoo! Finance]Yahoo! Finance
- Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal AdenocarcinomaGlobeNewswire
- Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of OsteosarcomaGlobeNewswire
LSTA
Earnings
- 5/9/23 - Beat
LSTA
Sec Filings
- 4/29/24 - Form DEFA14A
- 4/29/24 - Form DEF
- 4/24/24 - Form 3
- LSTA's page on the SEC website